Joel Szela, DO
Infectious Disease · Rochester Hills, MINPI 1073994158
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by AbbVie at 39.5% of the total. 2025 is the largest year on record at $317, 2.3 times the $138 reported in 2022.
Across 21 payments — averaging $25.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$215
- Shionogi Inc$79
- Paratek Pharmaceuticals, Inc.$73
- Viiv Healthcare Company$71
- Insmed, Inc.$53
- Gilead$29
- plus $23 from 1 others
What the payments were for
- Food & beverage$543100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 7 | $215 |
| Shionogi Inc | 3 | $79 |
| Paratek Pharmaceuticals, Inc. | 3 | $73 |
| Viiv Healthcare Company | 3 | $71 |
| Insmed, Inc. | 3 | $53 |
| Gilead | 1 | $29 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
How this compares
$543 in reported general payments places this provider in the 65th percentile of 257 infectious disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 12 | $29,909 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 13 | $5,082 |
| Cefepime Hcl | 19 | $4,396 |
| CeftriaxoneCeftriaxone Sodium | 31 | $3,170 |
| Vancomycin Hcl | 31 | $2,510 |
| Linezolid | 13 | $926 |
| Cefazolin Sodium | 17 | $514 |
| Penicillin V Potassium | 13 | $169 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Rochester Hills
- Bishr Al UjayliRochester Hills$2K
- Jinson JoseRochester Hills$2K
- Peter GulickLansing$850K
- Teena ChopraDetroit$328K
- Indira BrarDetroit$323K
- Keith KayeAnn Arbor$187K
- Rodger MacarthurDetroit$150K
- Chris FarnumLansing$102K
- Pranatharthi ChandrasekarDetroit$71K
- Mayur RameshDetroit$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.